When it comes to resource stocks, John Kaiser believes investors are in capitulation mode. In his Tuesday Discovery Watch interview, Mr. Kaiser suggests that may be the overriding reason why Great Bear Resources (Mixed; GBR) and Osisko Metals (Sunny; OM) stocks seemed unimpressed with the good news from both companies over the past week.
As we wrote Monday, our 30-day Pharmaceuticals Indicator (a sub-industry of Healthcare) seems to have a decent ability to time the group's highs and lows. As of mid-week, it appears the indicator has peaked at a level not seen since September. While this development should catch the interest of cannabis stock speculators as many of those companies are found in the Pharmaceuticals industry classification, it is worth noting that the group includes many non-cannabis names. Consequently, those looking to play the pharmaceuticals industry from the long side should consider a diversified approach. Fortunately, one of the biggest names in the Canadian industry is non-cannabis stock Bausch Health Companies (Sunny; BHC).
On Tuesday, BHC jumped 4.4%, outpacing pot stocks to lead the industry higher. In today's INK Morning report, we highlight BHC as a key player in the Canadian pharma group. Tomorrow, we will highlight the highest INK Edge ranked cannabis stock on our screens.
Join the Canadian Insider Club to get the Morning INK Report emailed to you every trading day. You will also enjoy an ad-free experience on this website plus much more. Click here to read about out the benefits of joining the club which helps to support this website.
INK Research Premium Services
Top Buys and Sells Past WeekTSX and TSXV stocks with most insider sellings in the past 7 days |
As we wrote in our Monday market update, our 30-day Pharmaceuticals Indicator seems to have a decent ability to time the group's highs and lows. When the indicator peaks above 200%, it represents a strong peak in insider buying that has, at times, coincided with a base in stock prices. As of Tuesday, it appears the indicator has peaked at a level not seen since September 2017. This development should catch the interest of cannabis stock speculators as many of those companies are found in the Pharmaceuticals industry classification.
Company fundamental and
price data sourced from © Thomson Reuters Limited. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent
of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for
any actions taken in reliance on such content. 'Thomson Reuters' and the Thomson Reuters logo are trademarks of
Thomson Reuters and its affiliated companies. 
